Herpes simplex virus type 1 (HSV-1) is a neurotropic virus that establishes a lifelong latent infection within the sensory nerve ganglia of humans, after it has been acquired by infection of the oral mucosa or eye. Reactivation from latency occurs sporadically and can result in either asymptomatic shedding or a lesion at the primary site of infection. While the majority of HSV-1 infections are subclinical, in some individuals, reactivation of the latent virus can cause recurrent keratitis and corneal scarring.
HSV keratitis is the most common cause of corneal blindness in the United States (17) , emphasizing the necessity for improved treatment strategies, especially since traditional vaccines are not beneficial in preventing initial HSV infection or recurrences (21) . While topical nucleoside analogue-based antiviral medications are effective in treating acute epithelial infections, they can be toxic to corneal and conjunctival cells, and some strains of HSV develop resistance. In the present study, we investigated the use of virally vectored ribozymes (Rz) engineered to cleave essential HSV genes as an alternative therapeutic strategy.
Ribozymes are RNA enzymes that promote a variety of reactions, usually involving cleaving or splicing of RNA molecules (5, 22) . While ribozymes are generally not as potent or convenient as RNA interference using small interfering RNAs (siRNAs), they are not known to initiate "off-target" effects through the binding of short sequences in the 3Ј untranslated region of unintended mRNAs, a common hazard with siRNAs.
Effective ribozyme inhibitors can be identified through a combination of cell-free kinetic testing and cell-based functional assays.
HSV-1 carries more than 80 genes, which are organized into three temporal expression classes, immediate early (alpha), early (beta), and late (gamma) (30) . The goal of this study was to evaluate the effects of targeting essential HSV-1 lytic gene RNAs for degradation, using hammerhead ribozymes. Since even the most efficient ribozyme would not be predicted to cleave 100% of the targeted viral RNA, we chose to identify the viral lytic gene mRNAs whose cleavage by ribozymes would result in a significant reduction in viral yield. We therefore designed hammerhead ribozymes to cleave mRNAs of four HSV-1 essential genes (ICP4, U L 20, U L 30, and U L 54), and these ribozymes were tested for their abilities to cleave the RNA targets in vitro and in vivo. Based on these initial cleavage analyses, the ribozyme that was ultimately selected targeted the gene product for the HSV late gene U L 20. An adenoviral vector was then used to express this ribozyme in cell culture or in mice to assess the ability of this ribozyme to inhibit HSV-1 replication.
Although the mechanism of HSV-1 virus maturation and egress to the extracellular space is not fully understood, it has been shown that U L 20 protein, an essential gene product, plays an important role in this aspect of viral replication in cell culture (1) . The HSV-1 U L 20 gene is highly conserved in alphaherpesviruses, e.g., varicella-zoster virus (4), bovine herpesvirus 1 (29) , and pseudorabies virus (15) , as well as in the gammaherpesvirus Marek's disease virus type 2 (12) . The U L 20 open reading frame, which is positionally conserved among alphaherpesvirus genomes, encodes a 222-amino-acid nonglycosylated membrane protein and is regulated as a ␥1 gene. Deletion of the HSV-1 U L 20 and the pseudorabies virus U L 20 genes has been shown to reduce infectious virus production by up to 100-fold compared to that of wild type (1, 6, 9) . In the absence of the U L 20 protein, virions are trapped in the perinuclear space, as well as in cytoplasmic vesicles of the host cell, and therefore, infectious virions are not released to the extracellular space. Although it has been recognized as a membrane protein, the U L 20 protein is also involved in Golgi apparatus-dependent glycosylation and cell surface expression of glycoprotein K; both glycoprotein K and U L 20 are required for syncytium formation during HSV-1 infection. Therefore, U L 20 is also involved in virus-induced cell fusion.
Previous attempts to inhibit HSV-1 replication by gene targeting have focused largely on inhibiting immediate early gene expression, e.g., that of ICP4 (27, 28) . In this study, the impact of knocking down a late gene of HSV-1 was addressed. Using an adenoviral vector to express a hammerhead ribozyme targeting U L 20 RNA (Ad-U L 20 Rz), expression of the U L 20 gene was significantly reduced, leading to an inhibition of HSV-1 viral replication in vitro and in vivo. These findings suggest a possible new approach for therapy for HSV-1 infections.
MATERIALS AND METHODS
Ribozyme kinetics in vitro. We selected several genes as ribozyme targets, based on their requirements for viral replication (18) . Cleavage sites for hammerhead ribozymes were selected as previously described (23) , and two ribozymes were tested for each target mRNA. Synthetic RNA oligonucleotides comprising hammerhead ribozymes and corresponding target sequences were purchased from Dharmacon, Inc. (Lafayette, CO). The cleavage activity of each ribozyme was studied kinetically, as described previously (8) .
Ribozyme cloning and packaging in an adenoviral vector. Ribozymes were cloned into the pAdlox shuttle plasmid (GenBank accession number R62024) for packaging into an adenoviral vector. The hammerhead ribozyme was cloned between the cytomegalovirus promoter sequence and the simian virus 40 poly(A) signal. Following cloning of the hammerhead ribozyme, we inserted a hairpin ribozyme that separates the antiviral hammerhead ribozyme from a downstream internal ribosome entry site-green fluorescent protein (IRES-GFP) element. The shuttle plasmid was then inserted into the 5 adenoviral vector backbone by a cis-acting replication element (CRE)-lox recombination. The recombinant vectors were then propagated in cre8 293 cells (11, 20) . Adenoviral purification was conducted using a Vivapure AdenoPACK 100 (Vivascience AG, Hannover, Germany). The virus particle concentration and the 293 cell infectious titer of the adenovirus stock were determined as described previously (20) . Two adenoviruses, 5, the parental vector for transgene packaging (11) , and Ad-GFP, which expresses GFP from the 5 backbone, were used as controls in this study.
HSV-1 preparation. A low-passage stock of HSV-1 strain 17synϩ was prepared from a master stock obtained from J. Stevens (UCLA). The drug-resistant strains of HSV-1, PAAr5 (2, 13), tkLTRZ1 (3, 14) , and ACGr4 (2), as well as their parental strain, KOS, were generously provided by D. Coen (Harvard Medical School). The HSV-1 virus was propagated and titrated on rabbit skin cells grown in minimal essential medium supplemented with 5% calf serum and antibiotics (26) .
Ribozyme inhibition of multiple-step HSV-1 replication. All infections were performed in triplicate. Three groups were included to test the effect of the ribozyme in a wild-type HSV-1 infection: mock treatment, 5 (backbone adenovirus), and Ad-U L 20 Rz. Each experiment was performed in triplicate. Rabbit skin cells were seeded at a density of 2 ϫ 10 5 cells per well (3.5 cm 2 ), followed by an adenoviral inoculation at a dose of 7.5 ϫ 10 4 virus particles per cell for 15 h. The infection of HSV-1 (17synϩ) was conducted at a multiplicity of infection (MOI) of 10 Ϫ3 for 24 h before cell lysates were harvested for titration. Titration was conducted by serial dilution of cell lysates, and PFU were counted on rabbit skin cells, in triplicate for each dilution. After the yields were calculated, average infectious yield values and standard deviations were calculated from the three separate replicates of each experiment.
Four groups were included to test the impact of the vector-expressed ribozyme on the replication of drug-resistant HSV-1 strains: mock infection and Ad-U L 20 Rz treatments were performed as described before; an adenovirus expressing GFP was used instead of 5, and an acyclovir (ACV) treatment (0.1 M) was included. The dosage of acyclovir was determined by the threshold dose needed to distinguish drug resistance of HSV-1 (25) . Forty-eight hours after infection with HSV-1, cell lysates were harvested for titration. Five HSV-1 strains were tested: the drug-sensitive strains 17synϩ and KOS and the drug-resistant isolates PAAr5, tkLTRZ1, and ACGr4.
Ribozyme inhibition of U L 20 expression. We evaluated the effect of the vectorexpressed U L 20 ribozyme on single-step growth of HSV-1 (strain 17synϩ). Each experiment was conducted in triplicate, and each experiment included three treatments: mock infection, Ad-GFP, and Ad-U L 20 Rz. After Ad-U L 20 Rz was inoculated as described above, HSV-1 infection was conducted at an MOI of 3 for 8 h before cell lysates were harvested using TRIzol reagent (Invitrogen, Carlsbad, CA). Total RNA and DNA were separated by following the manufacturer's recommendation, and total RNA was treated with RNase-free DNase (10) to remove the DNA contamination. Reverse transcription was conducted using a First-Strand cDNA synthesis kit (Amersham Biosciences, Piscataway, NJ), followed by real-time PCR (16) . Specific primers and probes for either the viral genes (Table 1) or the rabbit GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene were synthesized by Applied Biosystems (Foster City, CA).
Testing the ribozyme inhibition of HSV-1 encephalitis in mice. Six-week-old female ND4 Swiss mice (Harlan-Sprague Dawley, Inc.) were infected via the rear footpads as previously described (16) . Three groups of 10 mice were employed, and two independent experiments were conducted. First, 1.4 ϫ 10 10 virus particles of adenovirus (expressing either U L 20 Rz or GFP) or phosphate-buffered saline (PBS) in a volume of 10 l per footpad was combined with 40 l of 10% sterile saline solution and injected into both rear footpads. After 3 to 4 h, mice were inoculated again with 1.4 ϫ 10 10 virus particles of adenovirus (U L 20 Rz or GFP) or PBS applied topically to each rear footpad following light scarification of the footpad with an emery board. This second application of adenovirus or PBS was immediately followed by a topical application of HSV-1 (17synϩ) at a dose of 10 4 PFU per footpad.
RESULTS
Kinetic analysis of HSV-1 ribozymes. Initially, four essential HSV-1 genes were chosen as ribozyme targets, ICP4, U L 20, U L 30/DNA polymerase, and U L 54/ICP27. Two ribozyme cleavage sites were selected for each gene, based on their moderate GϩC content and their predicted accessibility within the mRNA (33) and on other established design and validation parameters for therapeutic ribozymes (7) . Sequences of ribozymes and their cleavage sequences are shown in Table 2 . The ribozymes were evaluated for their catalytic efficiency in vitro on synthetic target RNAs, using time course and multiple-turnover kinetic analysis. The time course of cleavage was (Fig. 1) . The dependence of the initial rates of cleavage on substrate concentration was then determined and analyzed using Lineweaver-Burk double-reciprocal plots to determine
, and k cat /K m values (Fig. 1C) . The value for k cat /K m , which is an estimate of catalytic efficiency, ranged from 0.01 for U L 20 Rz135 to 15.9 for U L 20 Rz154 (Table 3) . For each HSV-1 target gene, the most efficient ribozyme was chosen for analysis as an inhibitor of viral replication.
The HSV-1 U L 20 ribozyme was the most efficient at inhibiting HSV-1 replication in vitro. Synthetic ribozymes for each of the four genes were then transfected into rabbit skin cells and tested for their abilities to reduce viral yields following infection with HSV-1, as described in Materials and Methods. These analyses demonstrated that the U L 20 ribozyme consistently resulted in the greatest reduction in viral yields (data not shown). Ribozymes targeting immediate early genes (ICP4 and U L 54) did not lead to a significant inhibition in viral replication, but ICP4-Rz885 mRNA displayed low catalytic efficiency (k cat /K m ϭ 0.3), which may explain its low inhibition of replication.
The vector-expressed ribozyme targeting the HSV-1 U L 20 mRNA significantly reduced wild-type viral replication in rabbit skin cells. Based on a screening of the above-described results, the U L 20 Rz154 ribozyme was determined to be the most efficient at inhibiting HSV-1 infection following transfection. Therefore, a DNA cassette expressing U L 20 Rz154 was cloned into an adenoviral vector in order to provide a more efficient means of delivering this ribozyme for subsequent analyses. This adenoviral vector (Ad-U L 20 Rz154) was then tested for its ability to inhibit HSV-1 replication in rabbit skin cells. HSV-1 infection was conducted at a low MOI (10 Ϫ3 ), and the ribozyme was used to inhibit multistep HSV-1 viral replication. Ad-U L 20 Rz154 reduced HSV-1 wild-type viral replication by 83% compared with that of the control treatment (5) (P Ͻ 0.001), and no significant differences were observed between the groups that received no treatment and those that received 5 treatments (Fig. 2) .
Ad-U L 20 treatment blocked the U L 20 gene expression during HSV-1 infection of rabbit skin cells. Ad-U L 20 Rz154 was also tested with a one-step replication assay of HSV-1 following infection at an MOI of 3. As U L 20 is a late gene, an 8-h incubation was used to allow completion of late gene expression. The effect of U L 20 Rz154 on U L 20 expression at the mRNA level was assayed by reverse transcription, followed by real-time PCR. A 68% reduction in U L 20 mRNA level was detected by comparing results of the Ad-ribozyme treatment with that of the Ad-GFP treatment (P Ͻ 0.0005) (Fig. 3B) . There was also a 50% reduction in U L 20 mRNA level using Ad-GFP treatment relative to that of mock infection (P Ͻ 0.0004). It is therefore likely that preinfection of the cells with adenoviral vectors reduces the replication of HSV-1. DNA was also extracted from each infected sample, and the viral DNA level normalized to that of the endogenous cellular control (GAPDH) was also determined using real-time PCR (Fig. 3A) . A 54% reduction in viral DNA level was observed for the ribozyme treatment group compared to that of the Ad-GFP group (P Ͻ 0.004), but there were no significant differences between the DNA levels of the mock infection and those of the Ad-GFP treatments.
Ad-U L 20 Rz154 inhibits viral replication of HSV-1 drugresistant strains. Treatment with Ad-U L 20 Rz154 was compared with that with acyclovir, using multistep infection at an MOI of 10 Ϫ3 . Ad-U L 20 Rz154 significantly inhibited wild-type HSV-1 viral production (by 98% against 17synϩ and by 95% against KOS), and acyclovir treatment led to similar levels of inhibition (99% and 80%, respectively). However, acyclovir treatment was not effective against drug-resistant strains of HSV-1 (no significant differences in HSV yields), while the U L 20 ribozyme maintained its inhibitory effect. In the case of PAAr5 infection, the U L 20 ribozyme reduced viral production by 99%; reductions were 76% for tkLTRZ1 infection and 70% for ACGr4 infection (Fig. 4) . Therefore, knocking down the expression of the U L 20 gene led to a significant inhibition of HSV-1 viral replication in viral strains that were resistant to a conventional antiviral drug. It should be noted that the 70-to 100-fold reduction of viral yields shown in Fig. 4A and B are greater than those shown in Fig. 2 because the infectious virus was harvested at 48 h in the experiments shown in Fig. 4 as opposed to 24 h as shown in Fig. 2 . control groups (receiving Ad-GFP and PBS treatments) showed signs of encephalitis, including hind-limb paralysis, hunched posture, ruffled fur, ataxia, and weakness. Mice that eventually became nonresponsive and could not ambulate were euthanized. However, mice from the ribozyme treatment group remained healthy and active overall (though at a much later time point, two deaths were observed, and one mouse showed mild paralysis). With the HSV ribozyme treatment, 89% of animals survived, while 45% and 40% survival rates were observed for PBS-and Ad-GFP-treated controls, respectively (Fig. 5) . Kruskal-Wallis nonparametric analysis showed significant differences among the three groups (P ϭ 0.04).
To further investigate the ribozyme's impact on viral replication in vivo, an independent experiment was performed in which four or five mice per group (receiving the Ad-ribozyme or Ad-GFP control treatment, respectively) were sacrificed at 6 days postinfection, and the feet, dorsal root ganglia, and spinal cords were dissected. Real-time PCR was conducted to compare viral DNA levels from different tissues. While Adribozyme treatment resulted in decreased HSV-1 viral DNA recovery from all tissues, the decrease did not reach statistical significance. In the spinal cord assay, where day 6 represents the peak of viral DNA loads, Ad-ribozyme treatment reduced the amount of viral DNA by sixfold (Fig. 6 ).
DISCUSSION
In this study, hammerhead ribozymes were designed to limit the expression of several HSV-1 essential genes (ICP4, U L 54, U L 30, and U L 20). In vitro kinetic analysis led to the selection of ribozymes with the greatest potential for efficient target cleavage. Because the U L 20 Rz154 exhibited the most robust inhibition of viral replication following transfection, it was cloned into an Ad5 vector and tested further in vitro and in vivo.
Our best target and best ribozyme was the U L 20 gene, a ␥1 gene, encoding a membrane protein that is essential for viral intra-and extracellular egress, as well as intracellular transport of viral glycoproteins. The ribozyme targeting U L 20 mRNA, which also likely disrupts U L 20.5 mRNA (32), not only reduced the replication of wild-type HSV-1 (in strains 17synϩ and KOS) but also inhibited the replication of drug-resistant HSV-1 strains (PAAr5, tkLTRZ1, and ACGr4). Data presented here confirm that the U L 20 gene product of HSV-1 is The drug-resistant strain tkLTRZ1 viral replication was inhibited by ribozyme by 76% (P Ͻ 0.05), while there was no effect from ACV. (E) The double-mutant strain ACGr4 viral replication was inhibited by ribozyme by 70% (P Ͻ 0.006), while ACV had no effect. A control adenovirus, Ad-GFP, was included to assess vector effects. When U L 20 mRNA levels were evaluated for the ribozyme effect, Ad-GFP treatment led to an approximately 50% reduction (Fig. 3B) , and a similar reduction was observed at the level of mRNA for the viral DNA polymerase (data not shown). The Ad vectors we employed contained deletions in the E1 and E3 regions but still contained viral late genes. It is possible that Ad-GFP competed with HSV-1 for the usage of cellular machinery, e.g., RNA polymerase II, indirectly leading to a lower level of viral gene expression in the Ad-GFP treatment group. Overall, in spite of the nonspecific effect of adenovirus, U L 20 Rz154 reduced viral target gene expression and inhibited virus replication significantly compared with the Ad-GFP treatment.
An interesting finding from this study was the significant reduction in viral DNA yields observed when the U L 20 ribozyme was tested with a single-step infection assay (Fig. 3A) . It has been previously shown that U L 20 expression is diminished when HSV-1 DNA replication is blocked, consistent with the designation of U L 20 as a late gene (31) . It was therefore surprising that the inhibition of this late gene by the ribozyme following a high MOI resulted in a decrease in viral DNA accumulation. These results suggest that U L 20 expression provides a feedback signal to viral DNA synthesis.
The Ad-U L 20 Rz154 ribozyme was capable of inhibiting the replication of acyclovir-resistant strains of HSV-1 (PAAr5, tkLTRZ1, and ACGr4) (Fig. 4) , which were chosen because they represent two general drug resistance mechanisms: mutations in thymidine kinase and in DNA polymerase. Most of the antiviral drugs currently approved for treatment of HSV-1 infection are nucleotide analogs, which are either substrates of thymidine kinase that indirectly disrupt viral DNA synthesis or are incorporated into the elongated DNA strand and lead to premature termination. The treatment of patients, especially those with immune deficiency and repeated reactivations, with antivirals has led to the selection of drug-resistant viruses that results in the uncontrolled spread of HSV-1 infection. In some cases, these infections are lethal to patients. It is encouraging that a nucleic acid-based approach such as a ribozyme targeting Kruskal-Wallis nonparametric analysis shows significant differences among the three group, with a P value of 0.04; n ϭ 10 mice per group.
FIG. 6. Adenovirus (expressing either Ad-UL20 Rz or Ad-GFP) was inoculated on both rear footpads of mice, which were then infected with HSV-1. At 6 days postinfection of HSV-1, five mice from the control group and four from the ribozyme treatment group were sacrificed to collect tissue samples. Viral DNA levels (relative to that of GAPDH) in the spinal cord were assessed in these two groups by real-time PCR. Squares represent relative viral DNA levels from the control group; circles represent relative viral DNA levels from the Ad-ribozyme treatment group; bars indicate the mean of each group. The mouse footpad infection model offers an efficient approach with which to study HSV-1 viral neuroinvasion, neurovirulence, and latency. We applied Ad-U L 20 Rz154 to block the initial replication in footpad epithelium, thereby reducing the retrograde transport of HSV-1 to the dorsal root ganglion (24) . At an inoculum of 10 4 PFU of wild-type HSV-1, the viral replication in the footpad epithelium led to severe damage in the central nervous system, which caused death in 60% of our control animals. Pretreating the mouse footpad with Ad-ribozyme consistently led to a significant level of protection (an overall 89% survival rate) against the HSV-1 challenge. Despite the HSV challenge, most animals in this group remained healthy throughout the study; one mouse showed mild paralysis of the hind limbs but remained active after the study's end point. In contrast, in both of the control groups, death and the indication of severe damage in the central nervous system were observed.
Interestingly, the ribozyme targeting a late essential gene, U L 20, achieved the most significant therapeutic effect against HSV-1 infection in vitro and in vivo, in this study. Palliser et al. designed siRNAs against HSV-2 U L 27 and U L 29, which encode an envelope glycoprotein and a DNA binding protein, respectively (19) . Their results indicate that suppressing the expression of early/late genes of HSV has a greater impact on the virus lytic life cycle than inhibiting the expression of immediate early genes. Our results here demonstrated that targeting a late gene was more effective than targeting genes of the other kinetic classes. We hypothesize that significantly inhibiting viral protein production of genes encoding structural proteins or virion maturation might produce a more profound effect than inhibiting regulatory genes, whose products are required in smaller and nonstoichiometric amounts. We have extended this finding to demonstrate that a nucleic acid-based therapeutic agent (U L 20 Rz-154) targeting a late gene could inhibit the viral replication of drug-resistant HSV-1 strains and could limit the lethal effects of an HSV-1 infection in vivo. Our next step is to develop a delivery system that will permit longlasting expression of such therapeutics in the corneal epithelium.
